Visby Medical

Visby Medical

Provides rapid PCR tests for infections

About Visby Medical

Simplify's Rating
Why Visby Medical is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Differentiation

Industries

Healthcare

Company Size

51-200

Company Stage

Grant

Total Funding

$284.5M

Headquarters

San Jose, California

Founded

2012

Overview

Visby Medical specializes in rapid PCR tests for detecting infectious diseases, providing results in under 30 minutes. This is a major improvement over traditional PCR tests that can take days for results. Their clients are mainly healthcare providers in the U.S., and they produce portable PCR testing kits suitable for clinical and mobile lab use. What sets Visby apart is their compact, instrument-free design, allowing a PCR lab's functionality to fit in the palm of your hand. The goal of Visby Medical is to deliver accurate and quick results to enhance patient diagnosis and treatment, reducing the common issues of patient callbacks and follow-ups in healthcare. Their revenue comes from selling these testing kits, which are increasingly important in today's health landscape.

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA clearances enhance Visby's credibility in the diagnostics industry.
  • Visby secured $3.9M to enhance PCR diagnostics for antibiotic resistance detection.
  • Telehealth integration offers opportunities for Visby to enhance remote diagnosis and treatment.

What critics are saying

  • Increased competition from emerging startups threatens Visby's market share.
  • Technological advancements may render Visby's current technology obsolete without continuous innovation.
  • Reliance on external funding indicates potential financial vulnerability if funding sources diminish.

What makes Visby Medical unique

  • Visby Medical offers rapid PCR tests delivering results in under 30 minutes.
  • Their PCR tests are instrument-free and compact, fitting in the palm of your hand.
  • Visby Medical focuses on human-centric, technology-first device development for delightful user experience.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$284.5M

Above

Industry Average

Funded Over

6 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Health Insurance

Health Savings Account/Flexible Spending Account

401(k) Company Match

Unlimited Paid Time Off

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Fierce Biotech
Mar 28th, 2025
Visby Medical nets FDA clearance for completely at-home STI test

Last month, Visby also acquired a 510(k) clearance from the FDA for its point-of-care respiratory disease test, designed to catch influenza A and B as well as the coronavirus behind COVID-19.

BioSpace
Jan 15th, 2025
Visby Medical gets $3.9M for PCR tech

Visby Medical has secured an additional $3.9 million from CARB-X to enhance its PCR-based diagnostics for antibiotic resistance, building on a previous $1.2 million grant. The funding will aid in developing tools to detect resistance mutations in infections, starting with ciprofloxacin susceptibility in Neisseria gonorrhoeae. Visby aims to integrate these capabilities into its Sexual Health Test and develop a digital app for result interpretation.

PR Newswire
Jan 15th, 2025
Visby Medical Secures Additional $3.9M from CARB-X to Fight Antibiotic Resistance with PCR-Based Mutation Detection at the POC

SAN JOSE, Calif., Jan. 15, 2025 /PRNewswire/ - Visby Medical(TM), a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to accelerate its fight against antibiotic resistance.

360Dx
Feb 9th, 2024
Visby Medical Secures $1.8M From CARB-X for Gonorrhea and Drug Resistance MDx

The portable, instrument-free PCR test will be used to detect infections resistant to the frontline antibiotic ciprofloxacin and help reduce use of ceftriaxone.

News Medical
Feb 9th, 2024
CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea.

There are no jobs for Visby Medical right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →